Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. BioMérieux
  6. Summary
    BIM   FR0013280286

BIOMÉRIEUX

(BIM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
102.65(c) 101.7(c) 101(c) 101.45(c) 100.35 Last
108 553 94 083 117 580 150 939 39 641 Volume
+0.29% -0.93% -0.69% +0.45% -1.08% Change
More quotes
Estimated financial data (e)
Sales 2021 3 331 M 3 759 M 3 759 M
Net income 2021 555 M 626 M 626 M
Net cash position 2021 216 M 244 M 244 M
P/E ratio 2021 22,0x
Yield 2021 0,70%
Sales 2022 3 368 M 3 801 M 3 801 M
Net income 2022 457 M 516 M 516 M
Net cash position 2022 517 M 583 M 583 M
P/E ratio 2022 26,8x
Yield 2022 0,68%
Capitalization 12 005 M 13 542 M 13 549 M
EV / Sales 2021 3,54x
EV / Sales 2022 3,41x
Nbr of Employees 12 800
Free-Float 35,7%
More Financials
Company
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also... 
Read more
More about the company
Ratings of bioMérieux
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BIOMÉRIEUX
01/06BIOMERIEUX : French multidisciplinary consortium ARPEGE awarded public funding of close to..
PU
2021BIOMÉRIEUX : Monthly statement on outstanding equity shares and voting rights
CO
2021CORPORATE SOCIAL RESPONSIBILITY : bioMérieux recently received a series of official recogn..
PU
2021BioMérieux Raises Net Sales Expectations For 2021
MT
2021BIOMERIEUX : BioMérieux – Increased outlook for full-year 2021
PU
2021BIOMERIEUX : BioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant
PU
2021EUROPE : European shares end at record high on strong earnings
RE
2021Qiagen, BioMerieux Reportedly Exploring Merger
MT
2021Qiagen, bioMérieux in Merger Talks to Create Medical Diagnostics Behemoth
MT
2021European shares end at record high on strong earnings
RE
2021BIOMERIEUX : BioMérieux, Baxter International Receive CE Mark for Acute Kidney Injury Test
MT
2021BAXTER INTERNATIONAL : Secures CE Mark for Test Predicting Persistent Severe Acute Kidney ..
MT
2021Biom?rieux S.A. Raises Earnings Guidance for the Year 2021
CI
2021BIOMERIEUX : BioMérieux – Third-Quarter 2021 Business Review
PU
2021BIOMÉRIEUX : 3rd quarter earnings
CO
More news
News in other languages on BIOMÉRIEUX
01/06Le Nasdaq digère mal la galette
01/06EN DIRECT DES MARCHES : Carrefour, Crédit Agricole, Sodexo, ALD, Ubisoft, Valneva, Meta, F..
01/06BIOMERIEUX : ARPEGE, un consortium français pluridisciplinaire obtient un financement publ..
01/05La baisse cherche à emmerder la hausse
01/04L'Europe enchaîne les records, Omicron inquiète moins
More news
Analyst Recommendations on BIOMÉRIEUX
More recommendations
Stock Trading Strategies
BIOMÉRIEUX - 2021
Expectation of a turn-around
BUY
More Stock Trading Analysis
Analysis
Roche buys GenMark for $1.8 million to challenge test rivals
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMÉRIEUX
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 101,45 €
Average target price 129,95 €
Spread / Average Target 28,1%
EPS Revisions
Managers and Directors
Alexandre Mérieux Chairman & Chief Executive Officer
Guillaume Bouhours EVP-Finance, Purchasing & Information Systems
Alain Mérieux Founding Chairman
François Lacoste Executive Director-Research & Development
Mark Miller Executive Director-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOMÉRIEUX-18.78%13 542
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.8.35%23 030
10X GENOMICS, INC.-39.16%10 124
DIASORIN S.P.A.-20.84%8 182
NATERA, INC.-32.67%5 948
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.-6.36%5 129